SCHEMBL3070474

SCHEMBL3070474

Cc1cc(S)nc2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.64
BACE1 P56817 1/20 0.60
KDM4E B2RXH2 6/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
MAPT P10636 2/20 0.56
RAB9A P51151 2/20 0.56
POLB P06746 1/20 0.56
ALDH1A1 P00352 3/20 0.50
GAA P10253 3/20 0.50
NPFFR1 Q9GZQ6 1/20 0.50
NPFFR2 Q9Y5X5 1/20 0.50
SMN1; SMN2 Q16637 5/20 0.49
HPGD P15428 2/20 0.49
ACHE P22303 1/20 0.49
LMNA P02545 2/20 0.47
KMT2A Q03164 1/20 0.47
TP53 P04637 1/20 0.47
GPR3 P46089 1/20 0.47
NCF1 P14598 2/20 0.46
ADRB1 P08588 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7945687 0.98 CYP1A2 (0.62) CYP1A2BACE1KDM4EL3MBTL1MAPT
SCHEMBL29502790 0.78 CYP1A2 (1.00) CYP1A2BACE1KDM4EL3MBTL1MAPT
SCHEMBL89010 0.78 CYP1A2 (1.00) CYP1A2BACE1KDM4EL3MBTL1MAPT
SCHEMBL1088580 0.78 CYP1A2 (0.69) CYP1A2BACE1KDM4EL3MBTL1MAPT
Hydrochloric Acid SCHEMBL11674460 0.77 CYP1A2 (0.96) CYP1A2BACE1KDM4EL3MBTL1MAPT
SCHEMBL12997893 0.75 CYP1A2 (0.64) CYP1A2BACE1KDM4EL3MBTL1MAPT
SCHEMBL377555 0.75 CYP1A2 (0.64) CYP1A2BACE1KDM4EL3MBTL1MAPT
SCHEMBL22196103 0.75 CYP1A2 (0.64) CYP1A2BACE1KDM4EL3MBTL1MAPT
SCHEMBL3094768 0.75 BACE1 (1.00) CYP1A2BACE1KDM4EL3MBTL1MAPT
Iodide SCHEMBL4544205 0.75 CYP1A2 (0.64) CYP1A2BACE1KDM4EL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0677045-B1 CATALYTIC OXIDATION PROCESS OF THIOLS MONSANTO CO (US) 1999-02-10 EP claimed
EP-0677045-A1 CATALYTIC OXIDATION PROCESS MONSANTO COMPANY (US) 1995-10-18 EP claimed
WO-1994015927-A1 CATALYTIC OXIDATION PROCESS MONSANTO COMPANY (US) 1994-07-21 WO claimed
US-11382894-B2 Pharmaceutical compositions for use in the treatment of cardiovascular calcification INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2022-07-12 US disclosed
US-20210113527-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF CARDIOVASCULAR CALCIFICATION UNIVERSITE DE ROUEN NORMANDIE (FR) 2021-04-22 US disclosed
US-8399447-B2 Metal triangulo compound and methods of using the same NATIONAL UNIVERSITY OF SINGAPORE (SG) 2013-03-19 US disclosed
US-20100233415-A1 OPTICAL RECORDING MEDIUM AND AZO METAL CHELATE COMPOUND MITSUI CHEMICALS, INC. (JP) 2010-09-16 US disclosed
US-20100209431-A1 METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME NATIONAL UNIVERSITY OF SINGAPORE 2010-08-19 US disclosed
EP-2147005-A1 METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME National University of Singapore (SG) 2010-01-27 EP disclosed
EP-1997856-A1 OPTICAL RECORDING MEDIUM AND AZO METAL CHELATE COMPOUND Mitsui Chemicals, Inc. (JP) 2008-12-03 EP disclosed
WO-2008127197-A1 METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME NATIONAL UNIVERSITY OF SINGAPORE (SG) 2008-10-23 WO disclosed
EP-0677045-B1 CATALYTIC OXIDATION PROCESS OF THIOLS MONSANTO CO (US) 1999-02-10 EP disclosed
EP-0677045-A1 CATALYTIC OXIDATION PROCESS MONSANTO COMPANY (US) 1995-10-18 EP disclosed
EP-0417057-B1 Heterocyclic thiol-based sulfenimide compounds and rubber compositions containing them MONSANTO CO (US) 1995-03-01 EP disclosed
WO-1994015927-A1 CATALYTIC OXIDATION PROCESS MONSANTO COMPANY (US) 1994-07-21 WO disclosed
US-5260454-A Cure accelerator for natural and synthetic rubber; imroved cure rate, longer scorch delay MONSANTO COMPANY (US) 1993-11-09 US disclosed
US-5189174-A Rubber curing agent MONSANTO COMPANY (US) 1993-02-23 US disclosed
US-5079305-A Improved cure rate, scorch delay and reversion resistance MONSANTO COMPANY (US) 1992-01-07 US disclosed
EP-0417057-A2 Heterocyclic thiol-based sulfenimide compounds and rubber compositions containing them MONSANTO COMPANY (US) 1991-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100209431-A1 METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME CASP3, BAX, CASP7 CYP1A2 2659/4885BACE1 1188/4885KDM4E 3090/4885
US-11382894-B2 Pharmaceutical compositions for use in the treatment of cardiovascular calcification EPHX1, NCEH1, EPHX2 CYP1A2 1989/4885BACE1 557/4885KDM4E 1262/4885
US-20210113527-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF CARDIOVASCULAR CALCIFICATION EPHX1, NCEH1, ENPP1 CYP1A2 2729/4885BACE1 873/4885KDM4E 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.